Treating fatigue.
Fatigue is recognized as one of the most disabling and common symptoms of MS. However, no universal consensus has been reached regarding a formal definition for fatigue, and its mechanisms and causes are not understood. This review summarizes important research in this field and recommends a multidisciplinary approach to managing MS patients with fatigue. Such an approach should include proven pharmaceutical and non-pharmaceutical treatments.
Lapierre
Y
Y
Montreal Neurological Hospital/Institute, 3801 University, Montreal, Quebec, Canada H3A 2B4.
Hum
S
S
D000547:Amantadine / Q000627:therapeutic use*; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D015897:Comorbidity; D003937:Diagnosis, Differential; D015259:Dopamine Agents / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D005221:Fatigue / Q000188:drug therapy / Q000209:etiology / Q000628:therapy*; D006801:Humans; D009103:Multiple Sclerosis / Q000503:physiopathology*; D010348:Patient Care Team; D010389:Pemoline / Q000627:therapeutic use*
D000697:Central Nervous System Stimulants; D015259:Dopamine Agents; D010389:Pemoline; D000547:Amantadine